Bottlenecks of Immune Checkpoint Inhibitors in Treatment of Gastrointestinal Tumors

Immune checkpoint inhibitors (ICIs), as one of relatively advanced antitumor treatment methods in recent years, have achieved significant therapeutic effects in the treatment of multiple systemic tumors. However, their application in gastrointestinal tumors is not satisfactory, with treatment bottle...

Full description

Saved in:
Bibliographic Details
Main Authors: Chun HAN, Li BAI
Format: Article
Language:zho
Published: Magazine House of Cancer Research on Prevention and Treatment 2025-07-01
Series:Zhongliu Fangzhi Yanjiu
Subjects:
Online Access:http://www.zlfzyj.com/cn/article/doi/10.3971/j.issn.1000-8578.2025.24.1051
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850078035032670208
author Chun HAN
Li BAI
author_facet Chun HAN
Li BAI
author_sort Chun HAN
collection DOAJ
description Immune checkpoint inhibitors (ICIs), as one of relatively advanced antitumor treatment methods in recent years, have achieved significant therapeutic effects in the treatment of multiple systemic tumors. However, their application in gastrointestinal tumors is not satisfactory, with treatment bottlenecks. This article summarizes the challenges and possible solutions faced by ICIs in the treatment of gastrointestinal tumors to help clinicians better understand the limitations and future development directions of ICIs and thus develop more effective treatment strategies.
format Article
id doaj-art-5db0a6d92aa74b779d202ba726923b14
institution DOAJ
issn 1000-8578
language zho
publishDate 2025-07-01
publisher Magazine House of Cancer Research on Prevention and Treatment
record_format Article
series Zhongliu Fangzhi Yanjiu
spelling doaj-art-5db0a6d92aa74b779d202ba726923b142025-08-20T02:45:41ZzhoMagazine House of Cancer Research on Prevention and TreatmentZhongliu Fangzhi Yanjiu1000-85782025-07-0152753954710.3971/j.issn.1000-8578.2025.24.105120241051Bottlenecks of Immune Checkpoint Inhibitors in Treatment of Gastrointestinal TumorsChun HAN0Li BAI1Outpatient Chemotherapy Center, Beijing Arion Cancer Center, Beijing 102600, ChinaDepartment of Oncology, First Medical Center, General Hospital of Chinese People’s Liberation Army (PLA), Beijing 100853, ChinaImmune checkpoint inhibitors (ICIs), as one of relatively advanced antitumor treatment methods in recent years, have achieved significant therapeutic effects in the treatment of multiple systemic tumors. However, their application in gastrointestinal tumors is not satisfactory, with treatment bottlenecks. This article summarizes the challenges and possible solutions faced by ICIs in the treatment of gastrointestinal tumors to help clinicians better understand the limitations and future development directions of ICIs and thus develop more effective treatment strategies.http://www.zlfzyj.com/cn/article/doi/10.3971/j.issn.1000-8578.2025.24.1051icisgastrointestinal tumorstumor microenvironment (tme)inflammationgut microbiota
spellingShingle Chun HAN
Li BAI
Bottlenecks of Immune Checkpoint Inhibitors in Treatment of Gastrointestinal Tumors
Zhongliu Fangzhi Yanjiu
icis
gastrointestinal tumors
tumor microenvironment (tme)
inflammation
gut microbiota
title Bottlenecks of Immune Checkpoint Inhibitors in Treatment of Gastrointestinal Tumors
title_full Bottlenecks of Immune Checkpoint Inhibitors in Treatment of Gastrointestinal Tumors
title_fullStr Bottlenecks of Immune Checkpoint Inhibitors in Treatment of Gastrointestinal Tumors
title_full_unstemmed Bottlenecks of Immune Checkpoint Inhibitors in Treatment of Gastrointestinal Tumors
title_short Bottlenecks of Immune Checkpoint Inhibitors in Treatment of Gastrointestinal Tumors
title_sort bottlenecks of immune checkpoint inhibitors in treatment of gastrointestinal tumors
topic icis
gastrointestinal tumors
tumor microenvironment (tme)
inflammation
gut microbiota
url http://www.zlfzyj.com/cn/article/doi/10.3971/j.issn.1000-8578.2025.24.1051
work_keys_str_mv AT chunhan bottlenecksofimmunecheckpointinhibitorsintreatmentofgastrointestinaltumors
AT libai bottlenecksofimmunecheckpointinhibitorsintreatmentofgastrointestinaltumors